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Accumulating evidence demonstrates important roles for histone deacetylase in tumorigenesis (HDACs),
highlighting them as attractive targets for antitumor drug development. Histone deactylase inhibitors (HDACIs),
which have shown favorable anti-tumor activity with low toxicity in clinical investigations, are a promising class of
anticancer therapeutics. Here, we screened our compound library to explore small molecules that possess anti-
HDAC activity and identified a novel HDACI, YF479. Suberoylanilide hydroxamic acid (SAHA), which was the first
approved HDAC inhibitor for clinical treatment by the FDA, was as positive control in our experiments. We further
demonstrated YF479 abated cell viability, suppressed colony formation and tumor cell motility in vitro. To
investigate YF479 with superior pharmacodynamic properties, we developed spontaneous and experimental
breast cancer animal models. Our results showed YF479 significantly inhibited breast tumor growth and
metastasis in vivo. Further study indicated YF479 suppressed both early and end stages of metastatic progression.
Subsequent adjuvant chemotherapy animal experiment revealed the elimination of local-regional recurrence (LRR)
and distant metastasis by YF479. More important, YF479 remarkably prolonged the survival of tumor-bearing mice.
Intriguingly, YF479 displayed more potent anti-tumor activity in vitro and in vivo compared with SAHA. Together,
our results suggest that YF479, a novel HDACI, inhibits breast tumor growth, metastasis and recurrence. In light of
these results, YF479 may be an effective therapeutic option in clinical trials for patients burdened by breast cancer.
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Cancer has conventionally been considered as a disease involving
genetic defects that result in oncogene activation or loss of tumor
suppressor genes [1]. However, epigenetic changes including histone
acetylation, also contribute to tumor development [2]. Histone
acetyltransferases and deacetylases (HDACs) play a central role in
chromatin structure modification and gene expression [3,4]. Histone
acetyltransferase inactivation is associated with tumorigenesis [5].
Aberrant HDAC activity is proposed to be the key event in tumor
formation, since excessive HDAC activity inappropriately repressed
transcription of tumor suppressor genes [6].
Recently, more and more evidence has shown that HDAC inhibitors
induced tumor cell differentiation, apoptosis, and/or growth arrest in
several cell culture and tumor xenograft models. Based on the chemical
structure, HDACIs can be categorized into four main different classes,
including short-chain fatty acids, hydroxamates, benzamides and cyclic
tetrapeptides. The short-chain fatty acid sodium butyrate and the
hydroxamic acid trichostatin A were found relatively early to be HDAC
inhibitors, but both have limits to their clinical activity [7]. The
trichostatin A structural analog Suberoylanilide hydroxamic acid (SAHA)
has shown promise in cancer therapy. It was the first approved HDAC
inhibitor for clinical treatment by the FDA [8]. Other compounds from
structurally different families, such as LBH589, valproic acid, MS-275
and FK-228 have been used in pre- and clinical trials [9]. In addition,
several active trials of HDACI combined with other antitumor agents are
ongoing in patients with solid and hematological malignancies [10].
Breast cancer is the most common cancer diagnosed in women and
the second leading cause of cancer-related death worldwide [11].
Despite significant advances in the diagnosis and treatment of breast
cancer, many patients succumb to this disease. In recent years,
accumulating research strongly supports HDACs as molecular targets
for anticancer therapy in breast cancer [12,13]. Several HDACIs are
being evaluated as single agents or combined with conventional
therapies in clinical trials of metastatic breast cancer [12,14,15]. Based
on these backgrounds, it is necessary to develop novel HDAC
inhibitors for breast cancer therapeutics.
In this study, we identified a novel HDACI, YF479, which displays
potent anti-breast tumor activity. In vitro, YF479 inhibited cell
growth, induced apoptosis and G2/M cell cycle arrest, and suppressed
cell motility. We further demonstrated the inhibitory efficacy of
YF479 in breast cancer growth, metastasis and recurrence using
preclinical animal models. Interestingly, YF479 showed stronger anti-
tumor activity in vitro and in vivo compared to SAHA. In conclusion,
these findings provide the proof-of-concept for evaluation of YF479
as a breast cancer therapeutic agent.
Materials and Methods
Cell Culture, Animals, and Reagents
Breast tumor cell linesMDA-MB231, 4 T1 andT47Dwere obtained
from American Type Culture Collection. All these cells were maintained
in American Type Culture Collection recommended cell culture media
and conditions. MDA-MB231-luc (which stably expresses the luciferase
reporter gene and can be tracked by bioluminescence) was cultured in
MEM medium supplemented to 10% fetal bovine serum and
nonessential amino acids [16]. 4 T1-luc was cultured in DMEM
medium supplemented to 10% fetal bovine serum [17].
All animals were purchased from the National Rodent Laboratory
Animal Resources, Shanghai Branch of China. The mice were housedand maintained in the animal vivarium of East China Normal
University and all of the experimental protocols were approved by the
Animal Investigation Committee of the Institute of Biomedical
Sciences and School of Life Sciences, East China Normal University.
YF479 were synthesized as described in the Supplementary
Information. SAHA was described previously [18]. Compound
stock solutions were prepared in dimethyl sulfoxide (DMSO) at a
concentration of 50 mM and stored at −20°C. Matrigel was
purchased from BD biosciences. All antibodies were purchased
from Cell Signaling Technology, except anti-p21 (Santa Cruz) and
anti-actin (Sigma).
HDAC Activity Assay
HDAC activity was determined using the colorimetricHDAC activity
assay kit (BioVision, Inc.) according to the manufacturer's instruction.
Briefly, HDAC enzymes (Hela nuclear extract or MDA-MB231 cell
lysate) were incubated with SAHA or test compounds in the presence of
HDAC substrate (Boc-Lys (Ac)-AMC) at 37°C for 1 hour. Then the
lysine developer was added to terminate the reaction, and the samples
were incubated at 37°C for another 30 minutes. The fluorescence
intensities were determined in a fluorometer (FLUOstar OPTIMA,
BMG LABTECH) with excitation at 355 nm and emission at 460 nm.
Three independent experiments with triplicate were carried out.
Western Blot Analysis
MDA-MB231, 4 T1 or T47D were treated with YF479 or SAHA
for indicated time; then cells were lysed in RIPA buffer. Primary tumors
were well minced, and lysed with RIPA buffer. Protein concentration
was determined using a Bicinchoninic acid assay (Thermo Scientific).
Whole samples were run on 8% to 12% SDS-PAGE gels and
transferred to polyvinylidene difluoride membranes (Gibco). The
membranes were incubated overnight using specific antibodies. The
visual signals were visualized by chemiluminscence western blotting
reagent (ECL kit) and autoradiograph film.
Immunofluorescence Saining Assay
For immunofluorescence staining of tumor cells, human breast
tumor cells were plated onto gelatin-coated coverslips. After treatment
with or without compounds (as indicated in the figure) for 24 hours,
cells were fixed with 3.7% paraformaldehyde for 15 minutes at room
temperature, permeabilized with 0.1% Triton X-100 for 5 minutes,
and then blocked with 1% BSA for 1 hour. Cells were incubated with
specific primary antibody (as indicated in the figures) overnight. After
washing with PBS, cells were incubated with the appropriate secondary
antibody for 1 hour. Phalloidin and 4,6-diamidino-2-phenylindole
were further used to stain F-actin and nucleus, respectively.
Photographs were obtained with a Leica Confocal microscope.
MTS Assay
MDA-MB231, 4 T1 andT47D (5 × 103 cells/well) were treated with
various concentrations of YF479 for 48 hours. To detect cell viability,
the Aqueous one Solution (Promega) was used according to
manufacturer instructions, and the absorption of 490 nmwasmeasured.
Cell Cycle Analysis
Cell cycle analysis was conducted as described [19]. Briefly, MDA-
MB231 cells were treated with YF479 or SAHA for 24 hours
followed by PBS washes. Cells were then fixed with cold 70% ethanol
at 4 °C for at least 12 hours. PI working solution was added before
flow cytometry analysis (FACS Calibur, BDbiosciences).
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Apoptosis was measured using the Apoptosis Detection Kit (BD
Biosciences) as described [20]. Briefly, MDA-MB231, 4 T1 and
T47D cells were treated with YF479 or SAHA for 48 hours. Then
cells were collected, washed, and stained with annexin V–FITC and
PI for 15 minutes before evaluation by flow cytometry (FACS
Calibur, BDbiosciences).
Tumor Cell Clonogenic Assay
To mimic individual cell development into macroscopic cell clones,
the cell clonogenic assay was performed as previously described [21].
Tumor cells were seeded into 6-well plate and allowed to grow for
24 hours. Cells were then treated with different concentrations of YF479
or SAHA. On day 8, colonies were fixed in 3.7% paraformaldehyde,
stained with 0.1% crystal violet and counted manually.
Adhesion Assay
Adhesion assay was performed as previously reported [22] with
modifications. In brief, tumor cells were pretreated with DMSO or
different concentrations of YF479 for 12 hours, and then trypsinized.
Cells (1 × 105/well) were added into 96-well plates with or without
YF479 for 25 minutes at 37 °C. Non-adherent cells were removed by
a gentle wash with PBS and the remaining cells were stained with
0.1% crystal violet for 5 minutes. After extensive washing, the
precipitates were dissolved by addition of 30% acetic acid, and the
absorption was obtained at 590 nm. The percentage of inhibition was
expressed using control well as 100%.
Migration Assay
The inhibition of tumor cell migration by YF479 or SAHA was
determined by wound-healing migration assay [23]. Briefly, tumor cells
were allowed to grow into full confluence in 6-well plates, and then the
“wounds”were created by a sterile pipette tip. Freshmedium containing
10% fetal bovine serum and various concentrations of YF479 or SAHA
was added. After 12 hours incubation at 37 °C, cells were fixed with
3.7% paraformaldehyde and photographed. The migrated cells were
manually quantified. The percentage inhibition of migrated cells was
expressed using the untreated group as 100%.
Invasion Assay
Invasion assay was performed using transwell chambers (Corning)
with 8 μm pore membranes coated with Matrigel as described
previously [24]. In brief, after 12 hours pretreatment with YF479 or
SAHA in 6-well plate, tumor cells were detached with trypsin and
resuspended as signal cells. A total of 5 × 104 cells (for MDA-MB231)
or 10 × 104 cells (for 4 T1) in 100 μL of serum-free medium were
added in the upper chamber, and 600 μL of complete medium was
added at the bottom. Different concentrations of YF479 or SAHA
were added to both chambers. The cells were allowed to invade for
9–12 hours at 37 °C. Invaded cells were stained with 0.1% crystal
violet and counted manually. The percentage of inhibition was
expressed using control well as 100%.
Gelatin zymography assay
Gelatin zymography was performed as previously described [25].
Conditional media were collected after the cells were plated at equal
densities in 10 cm dishes and then serum starved in 5 ml of basal
media containing different concentrations of YF479 for 24 hours.
The conditional media were concentrated and equal amount ofsamples were mixed with sample buffer and applied to 8% SDS-
polyacrylamide gel copolymerized with 1 mg/mL of gelatin. After
running, the gel was incubated in renaturing buffer (2.5% Triton X-
100, 50 mM Tris-base, 200 mM NaCl, 10 mM CaCl2 and 1 μM
ZnCl2,) followed by a 24 hours incubation with developing buffer
(50 mM Tris-base, 200 mM NaCl, 10 mM CaCl2 and 1 μM
ZnCl2, 0.2% Brij35). The gel was then stained with 0.25%
coomassie blue R-250 for 1 hour and destained with coomassie
blue destaininig water. Clear bands against the dark blue background
where the protease has digested the gelatin indicated protease activity.
MDA-MB231 Xenograft Animal Model
MDA-MB231-luc cells (1 × 106 in 0.1 mL PBS) were inoculated
into the mammary fat pads of nude mice. On day 5, we used an
Xenogen IVIS 2000 Luminal Imager (IVIS imaging system 100,
Xenogen Corporation) to make sure the same number of tumor cells
were inoculated in each mouse, and then divided the mice into
4 groups (n = 6 per group). Thereafter, the mice received an i.p.
injection with YF479 (20 mg/kg or 30 mg/kg), SAHA (30 mg/kg) or
DMSO every day. The change of primary tumor size was monitored by
IVIS Imaging System. On day 30, mice were euthanized by cervical
dislocation under isoflurane anesthesia. Half of each primary tumor was
snap frozen in liquid nitrogen for western blotting. The other half were
fixed and prepared for immunohistochemical analyses. The excised
lungs were individually scanned for the presence of bioluminescent
metastatic cells.
Experimental Metastasis Animal Model
MDA-MB231-luc cells (1 × 106 in 0.1 mL PBS) were injected into
the lateral tail vein of female nude mice. The mice were then segregated
into 4 groups (n = 7 per group) based on initial IVIS image. Starting from
day 0, mice were administered with YF479 (20 mg/kg or 30 mg/kg),
SAHA (30 mg/kg) or DMSO every day. On day 30, after the last IVIS
detection, mice were euthanized and lung tissues were removed from
each mouse for immunohistochemical analyses.
Immunohistochemistry Analyses
Immunohistochemistry was performed as previously reported [21].
Primary tumors and lungs were excised, fixed and embedded in paraffin.
To investigate the effect of YF479 on tumor cells proliferation and
apoptosis in vivo, sections (4 μm) were stained with anti-proliferation
cell nuclear antigen (PCNA) and cleaved caspase-3. Images were
obtained with Leica microscope (Leica, DM4000b). The results were
analyzed using Image-Pro Plus 6.0 software.
Early and Advanced Metastasis Stage Animal Model
This animal experiment was performed as previously described [26].
MDA-MB231-luc cells (1 × 106 in 0.1 mL PBS) were injected into the
lateral tail vein of female nude mice which were subsequently divided
into 4 groups (n = 7 per group) according to the initial bioluminescence.
Two groups received early-stage treatment and were injected
intraperitoneally with YF479 (30 mg kg−1 day−1) or DMSO from
day 0 to day 7 and the other two groups received late-stage treatment,
injections from day 7 to day 15. On day 28, tumor cells in mice were
detected by Xenogen IVIS 2000 Luminal Imager.
Adjuvant therapy animal model
Adjuvant therapy animal experiment was performed as
previously described [27]. Mouse breast tumor cells 4 T1-luc
668 YF479 inhibited breast tumor growth, metastasis and recurrence Zhang et al. Neoplasia Vol. 16, No. 8, 2014(1 × 105 in 0.1 mL) were inoculated into the fourth mammary
fat-pad of female BALB/c mice. On day 8, mice were assigned
into four groups (n = 11 per group) and anesthetized, to
surgically removed the primary tumor; the wound was closed with
surgical clips. From day 9, YF479 (20 mg/kg or 30 mg/kg),
SAHA (30 mg/kg) or DMSO were administered every day by
intraperitoneal injection. Tumor recurrence and distant metastasisFigure 1. YF479 is a bona fide HDAC inhibitor. (A) Chemical structure o
lysates were treated with different dosages of YF479 or SAHA for 1 ho
were treated with YF479 or SAHA (at indicated concentration) for 24
histone H3,4 (Ac-H3, Ac-H4) levels. (E) MDA-MB231 cells were seede
for 24 hour, fixed, and stained with the indicated antibodies. (F) MDA-
24 hours. Western blotting was performed to analyze the expressio
experiments were repeated at least three times. **P b .01; ***P b .0in mice was monitored using in vivo bioluminescence imaging on
day 30.
Statistical Analysis
Unless otherwise noted, statistical analyses were performed using
the Student’s t-test. All experiments were repeated at least three times
except animal experiments. P b .05 was considered significant.f the HDACi, YF479. (B) and (C) Hela nuclear extract or MDA-MB231
ur, and HDAC activity wasmeasured. (D) MDA-MB231 or 4 T1 cells
hour. Western blotting was performed for analyzing the acetylated
d on gelatin-coated coverslips. Cells were then treated with YF479
MB231 cells were treated with YF479 (10 μM) or SAHA (10 μM) for
n of HDACs in MDA-MB231 cells treated with YF479 or SAHA. All
01.
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YF479 Is a Bona Fide HDAC Inhibitor
Using a HDACs inhibiton assay screen, we identified a novel
small molecule YF479 (N1-(3-bromobenzyl)-N7-hydroxy- N1-
(2,4-dimethoxyphenyl) heptanediamid; MW: 479.36) with the highest
HDAC inhibitory activity in our internal chemical library (about 150
compounds). The chemical structure was showed in Figure 1A. Further
synthesis experimental details and purity analysis are specified in
Supplementary Figure S1 and supplementary method. We tested the
histone deacetylase inhibitory activity of YF479 vis-a-vis that of SAHA
in detail. The results indicated YF479 and SAHA inhibited HDAC
activity in a dose-dependent manner (Figure 1, B and C) and the
inhibitory efficacy of YF479 was stronger than that of SAHA. A
hallmark index of HDAC inhibition in vivo is the acetylation of
histones H3 and H4 [28]. We therefore tested the effect of YF479 and
SAHA on the acetylation level of H3 and H4 via western blot and cell
immunofluorescence staining assay. As shown in Figure 1, D and E,
either YF479 or SAHA significantly upregulated acetylatedH3 andH4.
In addition, our data demonstrated that YF479 down-regulated the
expression ofHDAC 1, 2, 3, 4, 5 and 6 (Figure 1F). These initial results
suggested that YF479 is a bona fide HDACI, supporting further
examination of YF479 in breast cancer treatment in vitro and in vivo.
YF479 Soaks into HDACs in Docking Model
To explore how YF479 interacted with HDACs, molecular docking
models of YF479with x-ray crystal structure ofHDACs (HDAC1 (PDB
ID: 4BKX); HDAC2 (PDB ID: 3MAX) andHDAC3 (PDB ID: 4A69)
were carried out by the autodock 4.2 and UCSF Chimera 1.7. The
results from our predictive models showed that YF479 could bind to
the active domains of HDACs (Supplementary Figure S4). For
example, a hydrogen bond was observed to form by the N-H group of
imidazole of protonated His178 in HDAC1 with carbonyl group of
YF479 which was near the two aromatic groups (Supplementary
Figure S4a1). Through hydrophobic interaction, 3-bromophenyl
and 2, 4-dimethoxylphenyl in YF479 were approached the hydropho-
bic area which was formed by Pro 29, Phe 150, Phe 205, Leu 271 and
Tyr 303 residues. The alkyl liner could insert the pocket and interacted
with Phe 150 and Phe 205 residues (Supplementary Figure S4a2). The
hydroxamic group interacted with the zinc ion to form the coordinate
bond (Supplementary Figure S4A). For the HDAC2 (Supplementary
Figure S4B), a similar hydrogen bond was also observed to form by
His183 in HDAC2 with carbonyl group of YF479 which was near the
two aromatic groups (Supplementary Figure S4b1). Two phenyl groups
in YF479 interacted with the Pro34, Phe155, Tyr209, Leu276 and
Tyr308 of active site through hydrophobic interaction. The inhibitor
with alkyl linker could insert into the pocket and interact with the
hydrophobic area which was formed by Phe155 and Phe210 in this
pocket (Supplementary Figure S4b2). At last, the hydroxamic group
interactedwith the zinc ion to form the coordinate bond.We also found
that the interactions of YF479 with HDAC3 were similar to that with
HDAC1 or HDAC2 through analysis of docking models (Supplemen-
tary Figure S4C). From all the docking data of YF479 withHDACs, we
thought that YF479 could bind to HDACs with good interactions.
YF479 Retards Breast Cancer Cell Growth in Vitro
Tumor cells sustain limitless growth by continually proliferating
and evading apoptosis [29]. To determine the effect of YF479 on
breast cancer cell growth, we performed the MTS proliferation assay.As shown in Figure 2A, YF479 inhibited cell proliferation in a dose-
dependent manner in three different breast cancer cell lines, and the
IC50 ranged from 1 to 2.5 μM. Then, we evaluated whether the anti-
growth activity of YF479 was due to effects on cell cycle progression
and/or apoptosis. Our results showed that YF479 induced cell-cycle
arrest at the G2/M phase in MDA-MB231 cells and FACS analysis
showed increased cellular accumulation in the sub-G1 cell cycle
fraction, suggesting drug-induced tumor cell proliferation and
apoptosis (Figure 2B) [30,31]. Furthermore, YF479 caused a dose-
dependent induction of apoptosis as determined by Annexin V
staining (Figure 2C). We also studied the effect of YF479 on colony
formation, since colony formation of tumor cells is closer to its
physiology and growth in vivo. Results showed that YF479 (1 μM)
significantly inhibited MDA-MB231 and 4 T1 cells colony formation
(Figure 2D). Additionally, We performed western blotting assay to
detected the expression level of tumor cell proliferation (PCNA), cell
cycle (p21,cdc2 and cyclinB1) and apoptosis related proteins (PARP,
cleaved-PARP, caspase 3, and cleaved-caspase 3) after YF479 treatment
[32–35]. The result showed YF479 down-regulated the expression of
PCNA, cdc2, cyclinB1, PARP and caspase 3, while upregulated p21,
cleaved-caspase 3 and cleaved-PARP expression. SAHA was used as the
positive control in all the above assays (Figure 2E and Supplementary
Figure S5). These experiments suggested that YF479 suppressed breast
cancer cell growth, further supporting the testing of in vivo efficacy of
YF479 in breast cancer.
YF479 Shows Potent Metastasis-Inhibitory Effects on Human
and Murine Breast Cancer Cells
Tumor cell escape from the primary tumor to metastatic sites is a
multistep process, which requires loss of cell adhesion, and acquisition
of migration and invasion capability. To determine the effect of YF479
treatment on breast cancer metastasis, we performed cell adhesion,
migration, and invasion assays using highly malignant murine breast
cancer cell 4 T1 and human breast cancer cell MDA-MB231. YF479,
in a dose-dependent manner, significantly inhibited tumor cell
adhesion (Figure 3A panel a1), migration (Figure 3A panel a2), and
invasion (Figure 3A panel a3 and Figure 3B) in both 4 T1 and MDA-
MB231 breast cancer cells. In order to investigate whether the reduced
cell adhesion, and motility by YF479 were due to its growth
suppression activity, we performedMTS assay. Little growth inhibitory
effect of YF479 was observed within the same time frame as the cell
adhesion and motility assay (data not shown). Increasing evidence
shows the importance of paxillin in breast cancer morphology, invasion
and metastasis [36–38], and the paxillin signaling axis may represent a
potential therapeutic target and/or prognostic marker in breast cancer
metastasis [39]. To preliminarily explore the mechanism of YF479 on
anti-metastasis, we detected the expression of paxillin and the spindle
microtubule protein acetylated alpha-tubulin (Ac-tubulin), the marker
of primary cilia, which participates in the development and progression
of cancer, including breast cancer [40]. Results showed that YF479
significantly upregulated Ac-tubulin expression and markedly down-
regulated the expression of paxillin (Figure 3C). Matrix metallopro-
teinases (MMPs) play critical roles in cancer-cell invasion and
metastasis and numerous studies revealed inhibition of MMPs via
synthetic and natural inhibitor (TIMP: Tissue inhibitor of MMP)
suppress tumor cell invasion [41]. The result showed YF479 down-
regulated the expression level of MMPs (MMP2 and MMP9) and
upregulated TIMPs (TIMP1 and TIMP2) expression (Supplementary
Figure S6A). Furthermore, we found YF479 inhibited MMPs activity
Figure 2. YF479 inhibits breast tumor cell growth in vitro. (A) MDA-MB231, 4 T1 and T47D cells were treated with indicated concentrations of
YF479 for 48 hours. Cell viability was assessed by MTS assay (n = 3). (B) MDA-MB231, 4 T1 and T47D cells were treated with 5 μM YF479 or
5 μM SAHA for 24 hours. Cell cycle distribution was then evaluated using propidium iodide (PI) staining and flow cytometry (n = 3). (C) MDA-
MB231, 4 T1 and T47D cells were treated with indicated concentrations of YF479 and 5 μM SAHA for 48 hours. Apoptosis was assessed by
Annexin V/PI staining and flow cytometry (n = 3). (D) YF479 and SAHA abrogate cancer cell colony formation capacity (8 days). Number of
colonies counted in experiments repeated three times. Results represent the average of three replications. (E) MDA-MB231, 4 T1 or T47D cells
were incubatedwith various concentrations of YF479 and 5 μMSAHA for 48 hours. Effects on the expression of PCNA, p21, caspase 3, cleaved
–caspase 3, PARP and cleaved-PARP were determined by western blot. Actin was used as a loading control. **P b .01; ***P b .001.
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Figure 3. YF479 inhibits breast cancer cell adhesion, migration and invasion. (A) YF479 suppresses MDA-MB231 and 4 T1 breast cancer
cell adhesion, migration and invasion. a1, Adhesion assay. Tumor cells were pretreated with various concentrations of YF479 for
12 hours; Cells were trypsinized, and seeded on a fibronectin coated 96-well plate. After 25 minutes, non-adherent cells were removed
and adherent cells were stained with 0.1% crystal violet. The precipitates were dissolved in 30% acetic acid, and the absorption at
590 nm was acquired. a2, Wound-healing migration assay. Tumor cells were seeded in six-well plates. A “wound” was created after the
cells grew into full confluence, then different concentrations YF479 and SAHA were added. After incubation for 12 hours, all the groups
were fixed and photographed. a3, YF479 inhibits MDA-MB231 and 4 T1 invasion. Tumor cells were treated with different concentrations
of YF479 and allowed to invade through Matrigel. Invaded cell number was counted. (B) Representative images of a3. (C) MDA-MB231
cells were treated with YF479 for 24 hours. The immunofluorescence assay showed the expression level of paxillin and Ac-tubulin. All
experiments were repeated at least three times.
Neoplasia Vol. 16, No. 8, 2014 YF479 inhibited breast tumor growth, metastasis and recurrence Zhang et al. 671
672 YF479 inhibited breast tumor growth, metastasis and recurrence Zhang et al. Neoplasia Vol. 16, No. 8, 2014by gelatin zymography assay (Supplementary Figure S6B). Previous
study reported that SAHA limited tumor cell migration and invasion
[42], our results were in accordance with these studies (Supplementary
Figure S7). The above results suggested that YF479 showed metastasis-
inhibitory effects on human and murine breast cancer cells.YF479 Inhibits Tumor Growth and Metastasis in a Mouse
Orthotopic Implantation Model
Having shown the anti-tumor effects of YF479 in vitro, we next
determined whether these in vitro effects correlate with the in vivo
activity of YF479 using a mouse model. MDA-MB231-luc cells were
injected into the mammary fat pad of nude mice. Using whole-body
bioluminescence imaging, we monitored primary growth develop-
ment over 30 days. During 30 days, the rate of tumor growth
decreased in mice treated with YF479 (20 mg/kg and 30 mg/kg) or
SAHA (30 mg/kg), as compared with mice injected with DMSO
(Figure 4A). We found a significant different growth rate between
control and treated groups (30 mg/kg YF479) (p b 0.01) (Figure 4B).
All mice were sacrificed on day 30, and excised lungs were individually
scanned for the metastatic cells. Results of statistical analysis showed a
lower incidence of lungmetastasis in YF479-treatment groups than that
in the control group. Notably, the incidence of lung metastasis in the
YF479-treated mice (30 mg/kg) was lower than that in the SAHA-
treatment group under the same dosage (Figure 4C).
To better understand the mechanism by which YF479 suppressed
primary tumor growth, we analyzed tumor histone acetylation,
proliferation and apoptosis. The increased Ac-H3 and Ac-H4 levels in
primary tumor tissue of YF479 treated mice confirmed the HDAC
inhibitory effect of YF479 on breast cancer (Figure 4D). In addition,
results showed that YF479 more strongly increased Ac-H3 and Ac-
H4 levels. These results suggested that YF479 could effectively inhibit
HDAC activity in vivo. Histological analysis showed that the
expression of PCNA was decreased and cleaved-caspase 3 levels
were increased and the sensitivity of tumor apoptosis in the YF479-
treated group was higher than that in SAHA treated mice (Figure 4E),
which was in consistent with our results in vitro (Figure 2C).
YF479 Inhibits Breast Tumor Metastasis to the Lungs in an
Experimental Metastasis Animal Model
We have shown that YF479 inhibited breast cancer cell adhesion,
migration and invasion in vitro. Next, we tested the efficacy of YF479 in
attenuating the metastatic propensity of breast carcinoma cells using
an in vivo model of experimental metastasis. MDA-MB231-luc cells
were injected into the tail vein of female nude mice and the mice were
then treated with DMSO, YF479 (20 mg/kg, 30 mg/kg) or SAHA
(30 mg/kg). Due to size restrictions ofmurine capillaries, human tumor
cells are rarely able to pass from the arterial to the venous system (or vice
versa) by way of the lungs [43]. Therefore, shortly after tail vein
injection, all detectable cells became trapped in the lung (Figure 5A day
0). Within the first few days, there was a substantial attenuation of
bioluminescence signal in all groups (Figure 5A day 7). However, the
presence of MDA-MB231-luc cells in the lungs of YF479-treated mice
was much less than those in the control group after day 7 (Figure 5B).
Previous study showed that the experimental metastasis model finely
mimics both early stage (0–7 days) and late stage tumor metastasis. To
evaluate the inhibitory effect of YF479 on tumor cell proliferation and
apoptosis, we detected the expression of PCNA and cleaved-caspase
3 levels in lung sections.Our data indicated that YF479 inhibited tumorcell proliferation and induced tumor cell apoptosis in the lungs
(Figure 5C). Therefore, these results demonstrated that YF479 inhibits
breast tumor metastasis to the lungs.
YF479 Inhibits Cancer Metastasis to the Lungs at both Early
and Late Stages
The early stages of tumor metastasis result in the formation of
clinically occult micrometastatic foci and later stages primarily reflect
the progressive, organ-destructive growth of already advanced
metastases [44]. In vitro and in vivo experiments have shown that
YF479 inhibited tumor growth and metastasis. Here, we used an
animal model to investigate the effect of YF479 on early or late stages
of metastatic progression. To target early or late-stage metastasis
selectively, mice were administered with YF479 (30 mg/kg) either 0–7
or 7–15 d after intravenous injection of MDA-MB231-luc cells.
Intriguingly, YF479 significantly (P b .05) hindered both early-stage
and late-stage tumor metastases (Supplementary Figure S8). These
results indicated that YF479 inhibits tumor cell metastasis at any stages.
YF479 Suppresses Local-regional Recurrence, DistantMetastasis
and Prolongs Survival of Mice Orthotopically Implanted with
4 T1 Mammary Tumor Cells
The majority of invasive and noninvasive breast cancers are treated
today by breast conservation therapy (BCT), which includes wide local
excision and radiation treatment to the breast [45,46]. The incidence of
local-regional recurrence (LRR) and distant metastases after BCT is
positively correlated to the grade of malignancy [46]. Therefore, we
hypothesized that YF479 adjuvant treatment would reduce LRR,
inhibit distant metastasis formation, and prolong survival following
surgical resection of the initial breast tumor. To test this hypothesis, we
established the mouse 4 T1 mammary carcinoma model simulating an
adjuvant treatment condition. 4 T1 growth characteristics parallel
highly invasive human metastatic mammary carcinoma and the extent
of disease is comparable with human stage IV breast cancer [47]. Tumor
recurrence in mice was monitored using an in vivo bioluminescence
imager (Figure 6A). The incidence of recurrence in the control, YF479
(20 mg/kg, 30 mg/kg) and SAHA (30 mg/kg) treatment groups were
90.91% (10 of 11), 54.54% (6 of 11), 27.27% (3 of 11), and 45.45%
(5 of 11), respectively. Moreover, the respective incidences of distant
metastasis in the control group, YF479 and SAHA treatment groups
were 100% (11 of 11), 72.73% (8 of 11), 27.27% (3 of 11), and
54.54% (6 of 11) (Figure 6B). To detect whether the tumor suppression
effect of YF479 treatment could yield a survival benefit, survival rate
within the four groups was calculated. Our data showed that YF479
significantly increased the overall survival. By day 38, all the mice in
control group had died, while only one mouse died in YF479
treatment group (30 mg/kg). On day 54, seven YF479-treated mice
still lived (YF479 30 mg/kg) (Figure 6C). Altogether, YF479
suppressed local-regional recurrences and distant metastasis, and
prolonged the survival of mice with breast cancer.
The Potential Toxicity Test of YF479 on Mice
The potential toxicity of YF479 (30 mg kg−1 day−1) was detected
by measuring changes in body weight and observing the renal function,
hepatic function and other key organs by morphological analyses of
major organs compared with control. Our results indicated no obvious
architectural disarray following YF479 treatment (Supplementary
Figure S9). It implies that YF479 has few side effects on the mouse
body, at least under our therapeutic concentration.
Figure 4. YF479 inhibits breast tumor growth and metastasis in mouse orthotopic implantation model. MDA-MB231-luc cells (1 × 106) were
injected intomousemammary fat pads.Micewere divided into 4 groups (n= 6 per group) based on the initial bioluminescence obtained on day 5
after tumor cell implantation. (A) Temporal in vivo bioluminescence images ofmice bearing orthotropic (mammary fat pad)–injectedMDA-MB231-
luc cells. (B) Quantization of whole-body bioluminescence (total photon flux) in control and treatment groups. (C) Survey of metastasis site (lung)
monitored by ex vivo bioluminescence detection ofMDA-MB231-Luc cells in excised organ from control and treatment tumor-bearing nudemice.
(D) YF479 upregulated the expression of Ac-H3, H4 in primary tumor. (E) Immunohistochemical analysis of primary tumor sections showed YF479
inhibited tumor cell proliferation (PCNA) and induced apoptosis (cleaved-caspase 3). *P b .05; **P b .01; ***P b .001 versus control.
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Figure 5. Effect of YF479 on blocking breast tumor metastases to the lung in an experimental animal model. After tail vein injection of
MDA-MB231-luc cells (1 × 106), the mice were divided into four groups based on the initial bioluminescence images (n = 7 per group).
Bioluminescence images were obtained using a Xenogen IVIS 2000 Biophotonic Imager at indicated times. (A) Representative
bioluminescence images of mice inoculated with human MDA-MB231-luc cells in control and treatment groups. (B) Quantification of A.
(C) YF479 upregulated cleaved-caspase 3 expression and suppressed the expression of PCNA. *P b 0.05; *** P b .001 versus control.
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In recent years, different classes of HDAC inhibitors have been in
clinical investigation for the treatment of both hematologic and solid
tumors. Importantly, except for their antitumor activity, data from
clinical trials showed that HDAC inhibitors are well tolerated and
possess limited toxicities that are rapidly reversible upon discontin-
uation of the drug [14,48]. In this study, we identified a novel
hydroxamic acid-based HDACI, YF479. Our study showed that
YF479 exhibited potent breast tumor therapeutic efficacy in vitro
and in vivo.One of the important findings in this study is that YF479 displayed
satisfactory therapeutic effect in an adjuvant chemotherapy animal
model. The majority of breast cancers are treated by breast
conservation therapy (BCT), which includes wide local excision
and radiation treatment. A large percentage of breast cancers have
already metastasized before the removal of the localized primary
tumor. These metastases are always hard to detect, but once they
progress, they can lead to death. Adjuvant therapy of cancer following
primary resection is often used in an attempt to eradicate metastases,
and can lead to improved outcomes for patients [49]. Therefore,
Figure 6. YF479 suppresses local-regional recurrence and distant metastasis, and increases survival of mice with breast cancer. 4 T1-luc
cells (1 × 105) were injected into BALB/c mouse mammary fat pads. Primary mammary tumors were surgically removed 8 days after
inoculation, and mice were treated with DMSO, YF479 (30 mg/kg) or SAHA (30 mg/kg) (n = 11 per group). (A) Representative
bioluminescent images of mice in different groups. (B) Incidence of LRR and distant metastasis in each group. (C) Overall survival rate
according to treatment in the adjuvant treatment model was shown. Time scale relates to days after tumor resection.
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patients undergoing BCT. In our adjuvant therapy model, YF479
significantly reduced the incidence of LRR and distant metastasis.
More important, tumor-bearing mice treated with YF479 demon-
strated a tendency toward increased survival compared to control
mice (Figure 6). The most common type of LRR, present in 57% to
88% of patients, appears at the site of the primary breast cancer and
probably represents incomplete resection of the initial carcinoma.
Although we did not detect any tumor cells after primary tumor
resection by IVIS, it is possible that a few cells remained. This may
partially explain the phenomenon that the vast majority of recurrence
appears at the primary breast cancer site in mice. The inhibitory
efficacy of YF479 in LRR stemming from primary tumor incomplete
resection is likely due to its anti-tumor growth efficacy. Another
possible reason for local-regional recurrence or distant metastatic
growth in the lungs is the presence of disseminated tumor cells orcirculating tumor cells [50]. We speculated that YF479 suppressed
local recurrence or distant metastases via affecting disseminated tumor
cell or circulating tumor cell survival. These results also implied that
HDACs may play a critical role in tumor recurrence and distant
metastasis. In aggregate, our data showed that YF479 provides
significant clinical benefits in the treatment of breast cancer.
We have shown in this study that YF479 inhibited tumor growth
and metastasis using orthotopic implantation and experimental
animal models. Although clinical data showed that HDACIs have
only moderate effects on solid tumor growth, we still obtained
significant suppression of breast tumor growth by YF479. Interest-
ingly, YF479 has a stronger anti-tumor growth activity compared
with SAHA. We also believe that YF479 in combination with other
anti-tumor agents is a reasonable therapeutic strategy for breast cancer
progression. Metastasis is a complex process and one of the critical
steps during tumor metastasis is tumor cell migration and invasion,
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or the bloodstream as well as their extravasation into the target organs
[51]. Moreover, tumor metastasis still represents the major cause of
mortality, being responsible for 90% of all cancer deaths. Indeed, in
xenograft mouse models (Figures 4 and 5), metastasis (lung) was
found to be blocked in mice with YF479 treatment. Furthermore,
histological analysis demonstrated that YF479 induced tumor cell
proliferation arrest and apoptosis in secondary tumors. This data
implied that YF479 inhibited tumor metastasis partly via impeding
tumor growth in target organs (such as lungs).
Previous investigations indicated that the early stages of tumor
metastasis result in the formation of micro-metastatic foci and advanced
stages primarily reflect the progressive, organ-destructive growth of
already establishedmetastases [26]. Although themedical conditions and
means of diagnosis have greatly improved, patients who die from cancer
succumb to treatment-refractory metastatic progression. These results
may be caused by the limited function of some clinical and preclinical
drugs. For example, matrix metalloproteinase (MMP) inhibitors and the
fascin inhibitorMacroketone are only believed to impair initialmetastasis
events (early stage) [52,53]. Actually, effective anti-metastatic therapeutic
drugs, such as dasatinib, medroxyprogesterone acetate and LY2157299
(TGF-βR I kinase inhibitor) [44], must be capable of impairing
the proliferation and survival of already disseminated carcinoma cells.
Here, we demonstrated that YF479 suppressed both early stage and
advanced stage tumor metastasis (Supplementary Figure S8). These
results suggested that YF479 displays potential therapeutic effects in
clinical experiments.
Based on our studies, YF479 could be as a potential chemotherapy
agent for breast cancer growth, metastasis and recurrence. In in vitro
assays, while YF479 and SAHA both exhibited anti-breast tumor cell
growth and motility efficacy, YF479 displayed significantly higher
activity. Furthermore, YF479 abrogated cell growth, induced
significant G2/M cell cycle arrest, and enhanced apoptosis in both
human and mouse breast cancer cells. In addition, HDACIs also have
beneficial clinical therapeutic effects on several types of cancer (lung,
colorectal, sarcoma, etc.), and it will be essential to determine the
efficacy of YF479 against other cancer types. Future studies may
expand its role in combination with chemotherapy for breast cancer
and a broader spectrum of other tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.07.009.
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